Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

12.5%

1 terminated/withdrawn out of 8 trials

Success Rate

85.7%

-0.8% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 6 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1

4(66.7%)

N/A

2(33.3%)

6Total

Phase 1(4)

N/A(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT04249674Unknown

Impact of CYP2D6 Genetic Polymorphisms on the Vulnerability to Drug-drug Interactions With Tramadol

Role: collaborator

NCT04188028Not ApplicableCompleted

Endobiotics for Phenotyping of Human Cytochrome P450 Enzymes

Role: lead

NCT04996784Completed

Pharmacokinetics of Dexamethasone in COVID-19 Obese Patients

Role: lead

NCT03054220Not ApplicableCompleted

Impact of Genetic Polymorphism on Drug-Drug Interactions Involving CYP2D6

Role: lead

NCT03375034Phase 1Completed

Exploring the Role of the GABAergic Modulation in Pain Transmission in Human

Role: lead

NCT03054207Phase 1Terminated

Impact of Antiretroviral Treatment on Pharmacokinetics and Pharmacodynamics of Thienopyridines in Healthy Volunteers and HIV Patients

Role: lead

NCT02391688Phase 1Completed

Evaluation of the Potential Pharmacokinetic Interactions Between Probe Drugs in the Geneva Phenotyping Cocktail

Role: lead

NCT01731067Phase 1Completed

Cocktail Approach for Cytochrome P450 and P-glycoprotein Activity Assessment Using Dried Blood Spot

Role: lead

All 8 trials loaded